Dyadic International Inc. has announced a leadership change as part of its strategic shift towards focusing on ancillary recombinant protein products for life sciences, nutrition, and industrial applications. Joe Hazelton has been appointed as President, effective immediately, while continuing his role as Chief Operating Officer. This move aims to align the organization with its evolving strategy and capitalize on new market opportunities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.